Suppression of porcine hemagglutinating encephalomyelitis virus replication by resveratrol.
Antiviral activity
Betacoronavirus
Porcine hemagglutinating encephalomyelitis virus
Resveratrol
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
28 12 2022
28 12 2022
Historique:
received:
05
03
2022
accepted:
14
12
2022
entrez:
28
12
2022
pubmed:
29
12
2022
medline:
31
12
2022
Statut:
epublish
Résumé
Porcine hemagglutinating encephalomyelitis virus (PHEV), a member of the genus Betacoronavirus, is the causative agent of neurological disease in pigs. No effective therapeutics are currently available for PHEV infection. Resveratrol has been shown to exert neuroprotective and antiviral effects. Here resveratrol was investigated for its ability to inhibit PHEV replication in nerve cells and central nervous system tissues. Anti-PHEV effect of resveratrol was evaluated using an in vitro cell-based PHEV infection model and employing a mouse PHEV infection model. The collected cells or tissues were used for quantitative PCR analysis, western blot analysis, or indirect immunofluorescence assay. The supernatants were collected to quantify viral loads by TCID Our results showed that resveratrol treatment reduced PHEV titer in a dose-dependent manner, with a 50% inhibition concentration of 6.24 μM. A reduction of > 70% of viral protein expression and mRNA copy number and a 19-fold reduction of virus titer were achieved when infected cells were treated with 10 µM resveratrol in a pre-treatment assay. Quantitative PCR analysis and TCID These results indicated that resveratrol exerted antiviral effects under various drug treatment and virus infection conditions in vitro and holds promise as a treatment for PHEV infection in vivo.
Sections du résumé
BACKGROUND
Porcine hemagglutinating encephalomyelitis virus (PHEV), a member of the genus Betacoronavirus, is the causative agent of neurological disease in pigs. No effective therapeutics are currently available for PHEV infection. Resveratrol has been shown to exert neuroprotective and antiviral effects. Here resveratrol was investigated for its ability to inhibit PHEV replication in nerve cells and central nervous system tissues.
METHODS
Anti-PHEV effect of resveratrol was evaluated using an in vitro cell-based PHEV infection model and employing a mouse PHEV infection model. The collected cells or tissues were used for quantitative PCR analysis, western blot analysis, or indirect immunofluorescence assay. The supernatants were collected to quantify viral loads by TCID
RESULTS
Our results showed that resveratrol treatment reduced PHEV titer in a dose-dependent manner, with a 50% inhibition concentration of 6.24 μM. A reduction of > 70% of viral protein expression and mRNA copy number and a 19-fold reduction of virus titer were achieved when infected cells were treated with 10 µM resveratrol in a pre-treatment assay. Quantitative PCR analysis and TCID
CONCLUSION
These results indicated that resveratrol exerted antiviral effects under various drug treatment and virus infection conditions in vitro and holds promise as a treatment for PHEV infection in vivo.
Identifiants
pubmed: 36578037
doi: 10.1186/s12985-022-01953-5
pii: 10.1186/s12985-022-01953-5
pmc: PMC9795454
doi:
Substances chimiques
Resveratrol
Q369O8926L
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
226Informations de copyright
© 2022. The Author(s).
Références
Cell. 2020 Dec 10;183(6):1520-1535.e14
pubmed: 33157038
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1053-1060
pubmed: 32640417
Afr J Tradit Complement Altern Med. 2013 Nov 02;11(1):209-12
pubmed: 24653579
J Virol. 2019 Feb 19;93(5):
pubmed: 30541856
Eur Rev Med Pharmacol Sci. 2020 Jul;24(14):7834-7844
pubmed: 32744711
J Virol Methods. 2019 Jul;269:13-17
pubmed: 30959064
J Vis Exp. 2013 Apr 08;(74):
pubmed: 23608783
Front Neurosci. 2021 Dec 13;15:763476
pubmed: 34966254
J Virol. 2018 Jul 31;92(16):
pubmed: 29875237
Sci Rep. 2017 Aug 18;7(1):8782
pubmed: 28821840
J Med Virol. 2020 Jun;92(6):552-555
pubmed: 32104915
Arch Virol. 2022 May;167(5):1381-1385
pubmed: 35397684
Med Chem. 2014 May;10(3):237-45
pubmed: 24329932
PLoS Pathog. 2022 Jun 27;18(6):e1010667
pubmed: 35759516
J Virol. 2021 May 24;95(12):
pubmed: 33762411
J Virol. 2022 Jan 12;96(1):e0169521
pubmed: 34643429
Adv Exp Med Biol. 1998;440:601-7
pubmed: 9782335
Biochem J. 2021 Mar 12;478(5):1159-1173
pubmed: 33605996
Mol Neurobiol. 2020 Dec;57(12):5299-5306
pubmed: 32876841
Adv Exp Med Biol. 2019;1209:55-78
pubmed: 31728865
Clin Vaccine Immunol. 2012 Jul;19(7):1102-9
pubmed: 22518008
Curr Pharm Des. 2012;18(1):27-33
pubmed: 22211686
Adv Exp Med Biol. 1993;342:339-46
pubmed: 8209751
Virulence. 2020 Dec;11(1):805-810
pubmed: 32567972
J Exp Med. 2021 Mar 1;218(3):
pubmed: 33433624
Front Vet Sci. 2019 Feb 27;6:53
pubmed: 30873421
Vet Res. 2020 Nov 11;51(1):136
pubmed: 33176871
Chin Herb Med. 2020 Oct;12(4):349-358
pubmed: 32963508
Vet Microbiol. 2021 Feb;253:108958
pubmed: 33387911
Sci Rep. 2017 Apr 10;7:45723
pubmed: 28393840
Vet Microbiol. 2019 Jun;233:147-153
pubmed: 31176401
Front Pharmacol. 2021 Apr 22;12:644219
pubmed: 33967780
J Infect Dis. 2016 Mar 1;213(5):712-22
pubmed: 26486634
Adv Exp Med Biol. 1981;142:399-408
pubmed: 6278894
J Comp Pathol. 2004 Jan;130(1):58-65
pubmed: 14693125
Res Vet Sci. 1965 Oct;6(4):482-9
pubmed: 5893564
Virol Sin. 2021 Feb;36(1):141-144
pubmed: 32458296
Front Cell Dev Biol. 2018 Nov 19;6:155
pubmed: 30510929
Adipocyte. 2021 Dec;10(1):408-411
pubmed: 34402717
Nutrients. 2016 Apr 20;8(4):233
pubmed: 27104565
Nature. 2006 Nov 16;444(7117):337-42
pubmed: 17086191
J Virol. 2018 Aug 16;92(17):
pubmed: 29925652
Viruses. 2018 Aug 27;10(9):
pubmed: 30150559
Vet Rec. 1969 Jul 29;85(4):99-100
pubmed: 5387810
Can J Comp Med Vet Sci. 1962 Mar;26(3):49-56
pubmed: 17649356
Front Cell Infect Microbiol. 2017 Feb 28;7:56
pubmed: 28293544
mSphere. 2020 May 6;5(3):
pubmed: 32376700
J Infect Dis. 2017 Apr 15;215(8):1197-1206
pubmed: 28199701
Adv Virol. 2015;2015:184241
pubmed: 26693226
Front Biosci (Elite Ed). 2020 Jan 1;12(1):139-149
pubmed: 31585875
Viruses. 2021 Feb 23;13(2):
pubmed: 33672333
Plants (Basel). 2021 Feb 12;10(2):
pubmed: 33673026
Virol J. 2011 Mar 21;8:130
pubmed: 21418610
J Infect Dis. 2005 May 15;191(10):1719-29
pubmed: 15838800
Neurosci Lett. 2000 Mar 10;281(2-3):123-6
pubmed: 10704758
Emerg Infect Dis. 2017 Jul;23(7):1168-1171
pubmed: 28628449
J Comp Pathol. 2001 Jul;125(1):8-14
pubmed: 11437511
Methods Mol Biol. 2015;1282:1-23
pubmed: 25720466
Sci Rep. 2018 Sep 24;8(1):14257
pubmed: 30250304
Vet Microbiol. 2020 Oct;249:108849
pubmed: 32979750
BMC Infect Dis. 2017 Feb 13;17(1):144
pubmed: 28193191
J Gen Virol. 2014 Oct;95(Pt 10):2192-2203
pubmed: 24973237
Oxid Med Cell Longev. 2015;2015:837042
pubmed: 26221416
J Immunol. 2004 Sep 15;173(6):4030-9
pubmed: 15356152